Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 9/20 | 0.41 |
| ▸ | CDK2 | P24941 | 5/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802257 | 0.77 | CYP19A1 (0.52) | CDC7CDK2MAP3K14 | |
| SCHEMBL28441844 | 0.75 | SLC22A12 (0.53) | CDC7CDK2RAPGEF4SLC22A12 | |
| SCHEMBL4807470 | 0.74 | CYP11B2 (0.41) | CDC7CDK2RAPGEF4SLC22A12MAP3K14 | |
| SCHEMBL4808225 | 0.73 | CDK2 (0.46) | CDC7CDK2SLC22A12 | |
| SCHEMBL4809049 | 0.73 | ALOX15 (0.52) | RAPGEF4SLC22A12 | |
| SCHEMBL19644484 | 0.71 | RAPGEF4 (0.45) | CDC7CDK2RAPGEF4SLC22A12L3MBTL1 | |
| SCHEMBL30424543 | 0.70 | RAPGEF4 (0.56) | CDC7CDK2RAPGEF4SLC22A12CRHR1 | |
| SCHEMBL10094619 | 0.69 | CDC7 (0.50) | CDC7CDK2RAPGEF4SLC22A12L3MBTL1 | |
| SCHEMBL1836254 | 0.69 | CRHR1 (0.36) | CRHR1MAPKAPK2 | |
| SCHEMBL2184636 | 0.69 | GRM5 (0.54) | CDC7CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| WO-2008004117-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008004117-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PDE5A, PDE3B, PDE12 | CDC7 1474/4885CDK2 2090/4885RAPGEF4 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.